---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-202813"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:42:23.128682+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aligos Therapeutics effects 1-for-25 reverse stock split to meet Nasdaq listing requirement

## Summary
- Reverse split at 1-for-25 effective 12:01 a.m. ET on August 19, 2024; trading symbol ALGS unchanged.
- Split intended to bring company into compliance with Nasdaq minimum bid price for continued listing.
- Every 25 pre-split shares reclassified into one new share; par value unchanged at $0.0001.
- No fractional shares issued; holders entitled to cash payment based on August 16, 2024 closing price.
- Board approved split on July 24, 2024; final ratio set by Reverse Split Committee on August 6, 2024.

## SEC filing metadata
- accession: 0001193125-24-202813
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312524202813/0001193125-24-202813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312524202813/d882619d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-202813
- JSON: https://secwatch.observer/filing/0001193125-24-202813.json
- Plain text: https://secwatch.observer/filing/0001193125-24-202813.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.